Equity Profile

RVMD

Revolution Medicines, Inc.

Health CareBiotechnology$39.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how it compares to analyst expectations.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $39 billion, it operates in the health care sector, addressing significant unmet needs in oncology through targeted drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1-2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by 24.86%. The stock reacted positively, gaining 2.62% the following day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has consistently missed EPS estimates in recent quarters. Investors will be closely watching for any signs of improvement in financial performance.

Bull Case

If the company can show a significant reduction in losses or a surprise in revenue growth, it could bolster investor confidence and lead to a positive stock reaction.

Bear Case

Continued misses on EPS and lack of revenue growth could lead to further declines in stock price, especially given the high expectations reflected in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in assessing whether the company is making progress towards profitability and meeting investor expectations.

What revenue figures can we expect this quarter?

Revenue growth or decline will indicate market demand for the company's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Revolution Medicines' financials, given recent product developments that could drive revenue.

Supporting Evidence

Options are pricing a 7.42% move, indicating expectations of volatility that may not align with the company's actual performance.

The company's history of missing EPS estimates could be leading to overly cautious sentiment, despite potential improvements.

Key Risk

If the EPS comes in better than expected, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining the company's trajectory, especially given its recent history of misses.

Bull Confirmed If

An EPS improvement to -$1.50 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$2.50 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

If the company misses again, history suggests a slight decline, averaging around -0.14% in previous missed quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for existing therapies.
4Guidance on future revenue expectations.
5Any changes in strategic direction or partnerships.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how it compares to analyst expectations.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1-2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by 24.86%. The stock reacted positively, gaining 2.62% the following day despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has consistently missed EPS estimates in recent quarters. Investors will be closely watching for any signs of improvement in financial performance.

Bull Case

If the company can show a significant reduction in losses or a surprise in revenue growth, it could bolster investor confidence and lead to a positive stock reaction.

Bear Case

Continued misses on EPS and lack of revenue growth could lead to further declines in stock price, especially given the high expectations reflected in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in assessing whether the company is making progress towards profitability and meeting investor expectations.

What revenue figures can we expect this quarter?

Revenue growth or decline will indicate market demand for the company's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Revolution Medicines' financials, given recent product developments that could drive revenue.

Supporting Evidence

Options are pricing a 7.42% move, indicating expectations of volatility that may not align with the company's actual performance.

The company's history of missing EPS estimates could be leading to overly cautious sentiment, despite potential improvements.

Key Risk

If the EPS comes in better than expected, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining the company's trajectory, especially given its recent history of misses.

Bull Confirmed If

An EPS improvement to -$1.50 or better would confirm the bull case.

Bear Confirmed If

An EPS of -$2.50 or worse would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

If the company misses again, history suggests a slight decline, averaging around -0.14% in previous missed quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for existing therapies.
4Guidance on future revenue expectations.
5Any changes in strategic direction or partnerships.